With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

(MENAFN- EIN Presswire) EINPresswire/ -- "The Primary Biliary Cholangitis market is dominated by a mix of global leading pharmaceutical companies and emerging biotechnology innovators. Companies are ...

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, the FDA said in a safety communication on ...

Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to ...

Since my article from October, "What To Expect From Gilead in Q3 2025", Gilead Sciences' stock ( GILD) reached an all-time ...

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) – – XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine ...

In March this year, I flipped my rating on Mirum Pharmaceuticals, Inc. (MIRM) stock from the Sell rating I had given it in October 2024, to a Buy, in a note for Seeking Alpha. I am glad I did, as ...

On Nov. 1, 2025, roughly three years and a month after Bernice’s death, the class complaint was settled and PHSA, BCTS and ...

Each week we pay tribute to the loved ones remembered in our area with a funeral notice and online tribute page. To read the ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an ...